<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04917289</url>
  </required_header>
  <id_info>
    <org_study_id>ZSCTC3</org_study_id>
    <nct_id>NCT04917289</nct_id>
  </id_info>
  <brief_title>CTC vs Radiography as the Evidence of Recurrence in Colorectal Cancer Patients</brief_title>
  <official_title>Circulating Tumor Cell vs. Radiography as the Evidence of Disease Recurrence in Colorectal Cancer Patients Whose Tumor Underwent R0 Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study enrolled patients who underwent R0 resection of tumor and had elevated tumor&#xD;
      biomarkers (CEA, CA19-9). After enroll the study, a CTC test will performed and patients who&#xD;
      had positive CTC will be randomly assigned to two groups. The control group will continue&#xD;
      follow-up until radiological recurrence appear, the treatment group will start treatment or&#xD;
      change the current adjuvant regimen. First endpoint is OS. The secondary endpoint is DFS,&#xD;
      adverse event.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 year</time_frame>
    <description>Time from randomization to death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>3 year</time_frame>
    <description>Disease free time from randomization to death or recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>1 year</time_frame>
    <description>CTCAE adverse event of chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Circulating Tumor Cell</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive treatment or change current adjuvant therapy immediately after detecting CTC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in this arm will keep follow-up after detecting CTC until radiology evidence of recurrence appear.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Started chemotherapy or change the current adjuvant therapy</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-80 years;&#xD;
&#xD;
        Histologically proven colorectal cancer&#xD;
&#xD;
        All the lesion (s) has been R0 resected&#xD;
&#xD;
        Have elevated tumor biomarker (CEA or CA19-9) in three consecutive tests&#xD;
&#xD;
        More than 1 CTC has been detected (including 1)&#xD;
&#xD;
        ECOG 0-1&#xD;
&#xD;
        Hematology tests suggest that they can tolerate chemotherapy&#xD;
&#xD;
        Written informed consent for participation in the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have any radiological evidence of recurrence&#xD;
&#xD;
        Other previous malignancy within 5 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianmin Xu</last_name>
    <phone>+8613501984869</phone>
    <email>xujmin@aiiyun.com</email>
  </overall_contact>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2021</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

